{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:40:07Z","timestamp":1774489207372,"version":"3.50.1"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Overactive bladder (OAB) is a prevalent condition in men, often requiring pharmacologic treatment with anticholinergics or \u03b2-3 adrenergic receptor agonists. While effective in managing urinary symptoms, the impact of these therapies on male sexual function, particularly erectile function, remains underexplored and clinically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This manuscript reviews current evidence regarding the influence of OAB medications on male sexual function, with a focus on molecular mechanisms, clinical outcomes, and therapeutic implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review of preclinical and clinical literature was conducted to evaluate the effects of anticholinergics and \u03b2-3 agonists on erectile physiology and function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Molecular studies indicate that \u03b2-3 agonists may exert beneficial effects on erectile tissue via smooth muscle relaxation, independent of the NO-cGMP pathway. Clinical studies of mirabegron suggest variable improvements in erectile function, while vibegron shows benefits limited to intercourse satisfaction. Among anticholinergics, fesoterodine and tolterodine may have neutral or positive impacts on sexual function, although data are inconsistent across agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OAB pharmacotherapy may influence male sexual health; however, evidence remains mixed. Further high-quality research is needed to elucidate these relationships and guide individualized treatment strategies that address both urinary and sexual function in men.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/sxmrev\/qeag012","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:40:31Z","timestamp":1771591231000},"source":"Crossref","is-referenced-by-count":1,"title":["The effect of anticholinergics and\n                    <b>\u03b2<\/b>\n                    -3 agonists on erectile function: a narrative review"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-304X","authenticated-orcid":false,"given":"Selman","family":"Unal","sequence":"first","affiliation":[{"name":"Department of Urology, Urgup State Hospital , Nevsehir 50400 ,","place":["Turkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ege Can","family":"Serefoglu","sequence":"additional","affiliation":[{"name":"Department of Urology, Biruni University School of Medicine , Istanbul 34295 ,","place":["Turkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"1","key":"2026030611343638200_ref1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"issue":"12","key":"2026030611343638200_ref2","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1111\/j.1743-6109.2008.01000.x","article-title":"Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men","volume":"5","author":"Irwin","year":"2008","journal-title":"J Sex Med"},{"issue":"4","key":"2026030611343638200_ref3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11934-004-0047-1","article-title":"The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence","volume":"5","author":"McVary","year":"2004","journal-title":"Curr Urol Rep"},{"issue":"1","key":"2026030611343638200_ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(sici)1097-0045(19970915)33:1&lt;1::aid-pros1&gt;3.0.co;2-p","article-title":"Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide","volume":"33","author":"Bloch","year":"1997","journal-title":"Prostate"},{"issue":"4","key":"2026030611343638200_ref5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s001200050104","article-title":"Pattern of distribution of constitutive isoforms of NO synthase in the normal prostate and obstructive prostatic hyperplasia","volume":"36","author":"Klotz","year":"1997","journal-title":"Urologe A"},{"issue":"1","key":"2026030611343638200_ref6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1095\/biolreprod51.1.99","article-title":"Growth of the rat prostate gland is facilitated by the autonomic nervous system","volume":"51","author":"McVary","year":"1994","journal-title":"Biol Reprod"},{"issue":"1","key":"2026030611343638200_ref7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.1939-4640.2000.tb03276.x","article-title":"Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats","volume":"21","author":"Golomb","year":"2000","journal-title":"J Androl"},{"issue":"6","key":"2026030611343638200_ref8","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/S0022-5347(05)65050-1","article-title":"Enhanced force generation by corpus cavernosum smooth muscle in rabbits with partial bladder outlet obstruction","volume":"167","author":"Chang","year":"2002","journal-title":"J Urol"},{"issue":"5","key":"2026030611343638200_ref9","doi-asserted-by":"publisher","first-page":"F990","DOI":"10.1152\/ajprenal.00378.2002","article-title":"Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase","volume":"285","author":"Bing","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl 1","key":"2026030611343638200_ref10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1464-410x.1998.0820s1026.x","article-title":"Age-related erectile and voiding dysfunction: the role of arterial insufficiency","volume":"82","author":"Tarcan","year":"1998","journal-title":"Br J Urol"},{"issue":"2","key":"2026030611343638200_ref11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","article-title":"Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms","volume":"84","author":"Gravas","year":"2023","journal-title":"Eur Urol"},{"issue":"11","key":"2026030611343638200_ref12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1517\/17425255.2012.714365","article-title":"Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females","volume":"8","author":"Leone Roberti Maggiore","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"2026030611343638200_ref13","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-Aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective \u03b23-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2026030611343638200_ref14","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","article-title":"Effects of mirabegron, a novel \u03b23-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin","volume":"62","author":"Aizawa","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"2026030611343638200_ref15","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0022-5347(01)65752-5","article-title":"Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle","volume":"156","author":"Yamaguchi","year":"1996","journal-title":"J Urol"},{"issue":"4","key":"2026030611343638200_ref16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/s0022-5347(17)39653-2","article-title":"Characterization of muscarinic acetylcholine receptors in human penile corpus cavernosum: studies on whole tissue and cultured endothelium","volume":"144","author":"Traish","year":"1990","journal-title":"J Urol"},{"key":"2026030611343638200_ref17","doi-asserted-by":"publisher","first-page":"271.e1","DOI":"10.1016\/j.urology.2017.05.041","article-title":"The beneficial effect of Fesoterodine, a competitive muscarinic receptor antagonist on erectile dysfunction in streptozotocin-induced diabetic rats","volume":"107","author":"Yilmaz-Oral","year":"2017","journal-title":"Urology"},{"issue":"9","key":"2026030611343638200_ref18","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1073\/pnas.0931347100","article-title":"Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function","volume":"100","author":"Cirino","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030611343638200_ref19","doi-asserted-by":"publisher","first-page":"101707","DOI":"10.1016\/j.cont.2024.101707","article-title":"A historical perspective on anticholinergics in overactive bladder (OAB) treatment: \u201cfoundations, current practices, and future prospects\u201d","volume":"12","author":"Ochoa","year":"2024","journal-title":"Continence"},{"key":"2026030611343638200_ref20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.mjafi.2025.03.003","article-title":"Exploring the therapeutic potential of beta-3 adrenergic agonists in overactive bladder: a comprehensive review","volume":"82","author":"Nayak","year":"2025","journal-title":"Med J Armed Forces India"},{"issue":"3","key":"2026030611343638200_ref21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bju.13515","article-title":"Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?","volume":"118","author":"Gur","year":"2016","journal-title":"BJU Int"},{"issue":"4","key":"2026030611343638200_ref22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1055\/a-0869-7493","article-title":"Mirabegron, a selective \u03b23-adrenoceptor agonist causes an improvement in erectile dysfunction in diabetic rats","volume":"129","author":"Yilmaz-Oral","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"2026030611343638200_ref23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00210-002-0554-x","article-title":"M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland","volume":"366","author":"Ikeda","year":"2002","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"3","key":"2026030611343638200_ref24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/00002512-199506030-00007","article-title":"Oxybutynin","volume":"6","author":"Yarker","year":"1995","journal-title":"Drugs Aging"},{"issue":"21","key":"2026030611343638200_ref25","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.lfs.2004.11.013","article-title":"In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin","volume":"76","author":"Oki","year":"2005","journal-title":"Life Sci"},{"issue":"1","key":"2026030611343638200_ref26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF00372799","article-title":"Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome","volume":"4","author":"Milani","year":"1993","journal-title":"Int Urogynecol J"},{"issue":"3","key":"2026030611343638200_ref27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1590\/s1677-5538.Ibju.2015.0186","article-title":"Efficacy of tamsulosin, oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms","volume":"42","author":"Maldonado-Avila","year":"2016","journal-title":"Int Braz J Urol"},{"issue":"6","key":"2026030611343638200_ref28","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.ajog.2006.08.013","article-title":"The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter assessment of transdermal therapy in overactive bladder with oxybutynin trial","volume":"195","author":"Sand","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2026030611343638200_ref29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1464-410X.2006.06658.x","article-title":"Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study","volume":"99","author":"Sand","year":"2007","journal-title":"BJU Int"},{"issue":"6","key":"2026030611343638200_ref30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.sc.3100573","article-title":"Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction","volume":"36","author":"Vaidyananthan","year":"1998","journal-title":"Spinal Cord"},{"issue":"2-3","key":"2026030611343638200_ref31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0014-2999(97)89661-6","article-title":"Tolterodine--a new bladder-selective antimuscarinic agent","volume":"327","author":"Nilvebrant","year":"1997","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2026030611343638200_ref32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1124\/dmd.26.4.289","article-title":"Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes","volume":"26","author":"Postlind","year":"1998","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"2026030611343638200_ref33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","article-title":"Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine","volume":"40","author":"Olsson","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2026030611343638200_ref34","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.urology.2009.12.010","article-title":"Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates &gt;30 grams","volume":"75","author":"Chung","year":"2010","journal-title":"Urology"},{"issue":"6","key":"2026030611343638200_ref35","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","article-title":"Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"174","author":"Kaplan","year":"2005","journal-title":"J Urol"},{"issue":"6","key":"2026030611343638200_ref36","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/s0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"issue":"4","key":"2026030611343638200_ref37","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","article-title":"Clinical efficacy, safety, and tolerability of once-daily Fesoterodine in subjects with overactive bladder","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"issue":"6","key":"2026030611343638200_ref38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/00003495-200969060-00006","article-title":"Fesoterodine","volume":"69","author":"McKeage","year":"2009","journal-title":"Drugs"},{"issue":"6","key":"2026030611343638200_ref39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","article-title":"Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int J Impot Res"},{"issue":"9","key":"2026030611343638200_ref40","first-page":"1559","article-title":"Efficacy of tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients","volume":"19","author":"Dell'Atti","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1-3","key":"2026030611343638200_ref41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejphar.2009.04.068","article-title":"Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice","volume":"615","author":"Ito","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2026030611343638200_ref42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3810\/pgm.2008.07.1795","article-title":"Solifenacin at 3 years: a review of efficacy and safety","volume":"120","author":"Pelman","year":"2008","journal-title":"Postgrad Med"},{"issue":"5, Part 1","key":"2026030611343638200_ref43","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent Solifenacin succinate In patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"issue":"3","key":"2026030611343638200_ref44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of Solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"issue":"3","key":"2026030611343638200_ref45","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5213\/inj.2011.15.3.172","article-title":"Efficacy of anticholinergics for chronic prostatitis\/chronic pelvic pain syndrome in young and middle-aged patients: a single-blinded, prospective, multi-center study","volume":"15","author":"Kim","year":"2011","journal-title":"Int Neurourol J"},{"issue":"1","key":"2026030611343638200_ref46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4111\/kju.2011.52.1.49","article-title":"Impact of lower urinary tract symptoms\/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile function","volume":"52","author":"Seo","year":"2011","journal-title":"Korean J Urol"},{"issue":"9","key":"2026030611343638200_ref47","doi-asserted-by":"publisher","first-page":"608","DOI":"10.4111\/kju.2014.55.9.608","article-title":"Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin","volume":"55","author":"Ko","year":"2014","journal-title":"Korean J Urol"},{"issue":"7","key":"2026030611343638200_ref48","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1442-2042.2011.02772.x","article-title":"Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study","volume":"18","author":"Maselli","year":"2011","journal-title":"Int J Urol"},{"issue":"5","key":"2026030611343638200_ref49","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/s0022-5347(17)36966-5","article-title":"The American urological association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"issue":"11","key":"2026030611343638200_ref50","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jsxm.2018.09.011","article-title":"The risk of sexual dysfunction and effectiveness of treatment of benign prostatic hyperplasia with severe lower urinary tract dysfunction with combination of dutasteride and Solifenacin","volume":"15","author":"Kosilov","year":"2018","journal-title":"J Sex Med"},{"issue":"2","key":"2026030611343638200_ref51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.prnil.2019.11.005","article-title":"Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride","volume":"8","author":"Kosilov","year":"2020","journal-title":"Prostate Int"},{"issue":"1","key":"2026030611343638200_ref52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ajur.2021.04.002","article-title":"Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients","volume":"9","author":"Kosilov","year":"2022","journal-title":"Asian J Urol"},{"issue":"4","key":"2026030611343638200_ref53","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.urology.2004.04.056","article-title":"Male sexual health questionnaire (MSHQ): scale development and psychometric validation","volume":"64","author":"Rosen","year":"2004","journal-title":"Urology"},{"issue":"7","key":"2026030611343638200_ref54","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","article-title":"Clinical pharmacokinetics of Trospium chloride","volume":"44","author":"Doroshyenko","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2026030611343638200_ref55","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s43094-021-00311-6","article-title":"Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder","volume":"7","author":"Gundu","year":"2021","journal-title":"Future J Pharm Sci"},{"issue":"5","key":"2026030611343638200_ref56","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1590\/s1677-5538.Ibju.2018.0225","article-title":"Impact of overactive bladder on retrograde ejaculation","volume":"44","author":"Salvarci","year":"2018","journal-title":"Int Braz J Urol"},{"issue":"6","key":"2026030611343638200_ref57","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/nau.20420","article-title":"Beta3-adrenoceptors in urinary bladder","volume":"26","author":"Yamaguchi","year":"2007","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"2026030611343638200_ref58","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41443-021-00455-2","article-title":"Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study","volume":"34","author":"Karakus","year":"2022","journal-title":"Int J Impot Res"},{"issue":"5","key":"2026030611343638200_ref59","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/iju.14792","article-title":"Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: a randomized controlled trial","volume":"29","author":"Elbaz","year":"2022","journal-title":"Int J Urol"},{"issue":"6","key":"2026030611343638200_ref60","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1111\/j.1743-6109.2007.00600.x","article-title":"Validation of the erection hardness score","volume":"4","author":"Mulhall","year":"2007","journal-title":"J Sex Med"},{"issue":"4","key":"2026030611343638200_ref61","doi-asserted-by":"publisher","first-page":"e58175","DOI":"10.7759\/cureus.58175","article-title":"Effect of mirabegron in men with overactive bladder and erectile dysfunction: a prospective observational study","volume":"16","author":"Singh","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"2026030611343638200_ref62","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5213\/inj.2346148.074","article-title":"Comparative study between behavior therapy and behavior therapy plus mirabegron 50 mg in sexually active men with bothersome overactive bladder symptoms - a Multicenter, randomized study","volume":"27","author":"Lin","year":"2023","journal-title":"Int Neurourol J"},{"issue":"1","key":"2026030611343638200_ref63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/jcma.0000000000000208","article-title":"Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms","volume":"83","author":"Wu","year":"2020","journal-title":"J Chin Med Assoc"},{"issue":"2","key":"2026030611343638200_ref64","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.116.237313","article-title":"Pharmacological characterization of a novel Beta 3 adrenergic agonist, Vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder","volume":"360","author":"Di Salvo","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2026030611343638200_ref65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14656566.2020.1809652","article-title":"Evaluating vibegron for the treatment of overactive bladder","volume":"22","author":"Rechberger","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"13","key":"2026030611343638200_ref66","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133940","article-title":"The effects of Vibegron add-on therapy on alpha 1-blocker therapy for sexual function and overactive bladder symptoms in benign prostatic hyperplasia: a prospective, open-label study","volume":"13","author":"Yanagida","year":"2024","journal-title":"J Clin Med"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/smr\/article-pdf\/14\/1\/qeag012\/67259916\/qeag012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/smr\/article-pdf\/14\/1\/qeag012\/67259916\/qeag012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:34:45Z","timestamp":1772814885000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/smr\/article\/doi\/10.1093\/sxmrev\/qeag012\/8509380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/sxmrev\/qeag012","relation":{},"ISSN":["2050-0513","2050-0521"],"issn-type":[{"value":"2050-0513","type":"print"},{"value":"2050-0521","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"qeag012"}}